The nephrotoxic effect assesment of tuberculostatic drugs therapy by urinary enzymes Source: Eur Respir J 2004; 24: Suppl. 48, 654s Year: 2004
Evaluation of antituberculous drugs administration Source: Eur Respir J 2002; 20: Suppl. 38, 547s Year: 2002
Incidence and timing of hepatotoxicity due to anti-tuberculous treatment Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Evaluation of patient adherence to tuberculosis treatment by measuring drug metabolites in urine Source: Eur Respir J 2004; 24: Suppl. 48, 649s Year: 2004
Hepatotoxicity due to antituberculosis drug treatment Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis II Year: 2008
Paradoxical response to adequate antituberculosis treatment Source: Eur Respir J 2004; 24: Suppl. 48, 724s Year: 2004
Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid Source: Eur Respir J, 56 (4) 2000803; 10.1183/13993003.00803-2020 Year: 2020
Long-term antibiotic therapy Source: International Congress 2017 – PG3 Bronchiectasis Year: 2017
Noncompliance on antituberculosis treatment and the psychological profile Source: Eur Respir J 2001; 18: Suppl. 33, 467s Year: 2001
Fixed-dose combination antituberculosis therapy: is the INH dose adapted for the Tunisianpopulation? Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018
Safety and acceptability of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Side-effect in the treatment of pulmonary tuberculosis by first-line drugs Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities Year: 2009
Characteristics of patients who interrupted anti-tuberculosis treatment Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis Year: 2008
Impact of drug resistance over sputum conversion in tubercular patients receiving re-treatment regimen Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011
Efficacy of a standard chemotherapy regimen in the management of sputum-positive pulmonary TB relapses Source: Eur Respir J 2003; 22: Suppl. 45, 41s Year: 2003
Early dosing schedules of pyrazinamide-containing anti-TB treatment have no significant impact on drug-induced hepatitis Source: ISSN=ISSN 1810-6838, ISBN=, page=69 Year: 2007
Predictors of hepatotoxicity among patients with tuberculosis treated with antituberculous medication Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016